MINIMALLY INVASIVE PROCEDURE
Oasis has established an advanced technological platform of clinical-grade CAR-T cell preparation, developed a number of candidate CAR-T cellular products, and continuously optimized this technological platform to develop the next generation of CAR-T cellular products. Products include Car-T for Cancer and Car-T for Covid-19. We continue to be at the forefront of a powerful form of immunotherapy known as chimeric antigen receptor (CAR) T cell therapy. Using this approach, immune cells are taken from a patient’s bloodstream, reprogrammed to recognize and attack a specific protein found in cancer cells, then reintroduced into the patient’s system, where they get to work destroying targeted tumor cells.